Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups

Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors

Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time 

In the NICHE-3 study, all patients achieved a pathological response  

Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed 

Disappointing results were reported from the phase III MANTRA trial, but biomarker-based approaches still offer hope for MDM2 inhibition in solid tumours 

Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas 

In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types

Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease

Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers